Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
GLOBETECH PUBLISHING LLC
Schiller

Radiotherapy for Brain Cancer May Be Improved by Blocking DNA Repair Processes

By Medimaging International staff writers
Posted on 30 Apr 2014
Researchers have demonstrated in both cancer cell lines and mice that shutting down critical DNA repair processes could enhance the effectiveness of radiation therapy for highly fatal brain tumors called glioblastomas.

Radiation therapy causes double-strand breaks in DNA that must be fixed for tumors to keep growing. Scientists have long theorized that if they could find a way to block repairs from being made, they could prevent tumors from growing or at least slow down the growth, thereby extending patients' survival. Blocking DNA repair is a particularly attractive strategy for treating glioblastomas, as these tumors are highly resistant to radiation therapy. In a new study, University of Texas (UT) Southwestern Medical Center (Dallas, USA) researchers demonstrated that the hypothesis actually works in the context of glioblastomas.

“This work is informative because the findings show that blocking the repair of DNA double-strand breaks could be a viable option for improving radiation therapy of glioblastomas,” said Dr. Sandeep Burma, associate professor of radiation oncology in the division of molecular radiation biology at UT Southwestern.

Dr. Burma researches the determination of basic mechanisms by which DNA breaks are repaired, with the translational objective of improving cancer therapy with DNA-damaging agents. Recent research from his lab has demonstrated how a cell makes the choice between two major pathways that are used to repair DNA breaks—non-homologous end joining (NHEJ) and homologous recombination (HR). His lab found that enzymes involved in cell division called cyclin-dependent kinases (CDKs) activate HR by phosphorylating a key protein, EXO1. In this manner, the use of HR is coupled to the cell division cycle, and this has important implications for cancer therapeutics. These findings were published April 7, 2014, in the journal Nature Communications.

Whereas this study describes how the cell chooses between NHEJ and HR, a translational study from the Burma lab demonstrates how blocking both repair pathways can improve radiotherapy of glioblastomas. Researchers in the lab first were able to show in glioblastoma cell lines that a drug called NVP-BEZ235, which is in clinical trials for other solid tumors, can also suppress two key DNA repair enzymes, DNA-PKcs and ATM, which are crucial for NHEJ and HR, respectively. While the drug by itself had limited effect, when combined with radiation therapy, the tumor cells could not quickly repair their DNA, stalling their growth.

Although enthusiastic by the early findings in cell lines, the scientists remained guarded because earlier efforts to identify DNA repair inhibitors were not successful when used in living models—mice with glioblastomas. Drugs developed to treat brain tumors also must cross what's known as the blood-brain-barrier in living models.

However, the NVP-BEZ235 drug could effectively cross the blood-brain barrier, and when given to mice with glioblastomas and combined with radiation, the tumor growth in mice was inhibited and the mice survived a lot longer, up to 60 days compared to approximately 10 days with the drug or radiation therapy alone. These findings were published in a recent issue of Clinical Cancer Research.

“The consequence is striking,” said Dr. Burma. “If you irradiate the tumors, nothing much happens because they grow right through radiation. Give the drug alone, and again, nothing much happens. But when you give the two together, tumor growth is delayed significantly. The drug has a very striking synergistic effect when given with radiation.”

The combination effect is significant because the conventional therapy for glioblastomas in humans is radiation therapy; therefore, finding a drug that enhances the effectiveness of radiation therapy could have profound clinical importance eventually. For example, such drugs may permit lower doses of X-rays and gamma rays to be used for traditional therapies, thereby causing fewer side effects. “Radiation is still the mainstay of therapy, so we have to have something that will work with the mainstay of therapy,” Dr. Burma said.

Whereas the findings provide evidence that the theory of “radiosensitizing” glioblastomas works in mouse models, additional research and clinical trials will be needed to show whether the combination of radiation with DNA repair inhibitors would be effective in humans, Dr. Burma cautioned. “Double-strand DNA breaks are a double-edged sword,” he said. “On one hand, they cause cancer. On the other, we use ionizing radiation and chemotherapy to cause double-strand breaks to treat the disease.”

“Heavy particles cause dense tracks of damage, which are very hard to repair,” Dr. Burma noted. “With gamma or X-rays, which are used in medical therapy, the damage is diffuse and is repaired within a day. If you examine a mouse brain irradiated with heavy particles, the damage is repaired slowly and can last for months.”

These findings, published March 17, 2014, in the journal Oncogene, suggest that glioblastoma risk from heavier particles is much higher compared to that from gamma or X-rays. This study is relevant to the medical field, since ionizing radiation, even low doses from computed tomography (CT) scans, have been reported to increase the risk of brain tumors, according to Dr. Burma.

Related Links:

University of Texas Southwestern Medical Center



Supersonic Imagine
PCI Precision Charts
ARAB HEALTH

Channels

MRI

view channel
Image: Head impact telemetry system (HITs) helmet-mounted accelerometers are used in youth and collegiate football to evaluate the frequency and severity of helmet impacts (Photo courtesy of RSNA).

DTI-MRI Shows Brain Alterations in High School Football Players After Only One Season

Some high school football players exhibit measurable brain alterations after only one season of play, even in the absence of concussion. The new findings were presented at the annual meeting of the... Read more

General/Advanced Imaging

view channel
Image: The DermSpectra total body digital skin imaging system (Photo courtesy of DermSpectra).

Total Body Digital Skin Imaging System Developed for Dermatology and Primary Care Practices

A total body digital skin imaging system enables physicians to track critical skin changes (skin cancers, eczema, lesions, psoriasis, and rashes) in their office, over time. The DermSpectra (Tucson,... Read more

Imaging IT

view channel
Image: The DCMSYS Interface WebBridge is designed to connect to DCMSYS product range to access all the patient data, search studies, link data to the appropriate study and store, modify, share, and connect to any repository (Photo courtesy of Dicom Systems).

WebBridge Software for Medical Facilities Allows Third-Party Interfaces to Develop Front-End Functionality in a Matter of Days

Designed for medical facilities of any size, new web software allows any native or web-based third-party application to upload any non-standard data (e.g., JPEG, TFF, PDF, TXT, etc.) to an enterprise imaging... Read more

Industry News

view channel

X-Ray and Digital X-Ray Sector Nears USD 8 Billion in 2014

The market for both traditional and digital X-ray systems is estimated to reach USD 7.9 billion in 2014, according to a recent report from an international market research company. The healthcare market research publisher noted that upgrades of existing equipment and the rising incidence of disease are fueling the market.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.